AAAAAA

   
Results: 1-8 |
Results: 8
TUBULIN FROM PACLITAXEL-RESISTANT CELLS AS A PROBE FOR NOVEL ANTIMICROTUBULE AGENTS
Authors: SACKETT DL GIANNAKAKOU P PORUCHYNSKY M FOJO A
Citation: Dl. Sackett et al., TUBULIN FROM PACLITAXEL-RESISTANT CELLS AS A PROBE FOR NOVEL ANTIMICROTUBULE AGENTS, Cancer chemotherapy and pharmacology, 40(3), 1997, pp. 228-232
BCL-2 PROTEIN DOWN-REGULATION IS NOT REQUIRED FOR DIFFERENTIATION OF MULTIDRUG-RESISTANT HL-60 LEUKEMIA-CELLS
Authors: BLAGOSKLONNY MV ALVAREZ M FOJO A NECKERS LM
Citation: Mv. Blagosklonny et al., BCL-2 PROTEIN DOWN-REGULATION IS NOT REQUIRED FOR DIFFERENTIATION OF MULTIDRUG-RESISTANT HL-60 LEUKEMIA-CELLS, Leukemia research, 20(2), 1996, pp. 101-107
CONTROLLED TRIAL OF DEXVERAPAMIL, A MODULATOR OF MULTIDRUG-RESISTANCE, IN LYMPHOMAS REFRACTORY TO EPOCH CHEMOTHERAPY
Authors: WILSON WH BATES SE FOJO A BRYANT G ZHAN Z REGIS J WITTES RE JAFFE ES STEINBERG SM HERDT J CHABNER BA
Citation: Wh. Wilson et al., CONTROLLED TRIAL OF DEXVERAPAMIL, A MODULATOR OF MULTIDRUG-RESISTANCE, IN LYMPHOMAS REFRACTORY TO EPOCH CHEMOTHERAPY, Journal of clinical oncology, 13(8), 1995, pp. 1995-2004
PHASE-II STUDY OF PACLITAXEL IN RELAPSED NON-HODGKINS-LYMPHOMAS
Authors: WILSON WH CHABNER BA BRYANT G BATES S FOJO A REGIS J JAFFE ES STEINBERG SM GOLDSPIEL BR CHESON BD WITTES RE
Citation: Wh. Wilson et al., PHASE-II STUDY OF PACLITAXEL IN RELAPSED NON-HODGKINS-LYMPHOMAS, Journal of clinical oncology, 13(2), 1995, pp. 381-386
EXPRESSION OF MDR-1 IN REFRACTORY LYMPHOMA - QUANTITATION BY POLYMERASE CHAIN-REACTION AND VALIDATION OF THE ASSAY
Authors: KANG YK ZHAN ZR REGIS J ROBEY R MEADOWS B DICKSTEIN B LEE JS OTSUKI T STETLERSTEVENSON M JAFFE ES SOLOMON D WILSON WH FOJO A BATES SE
Citation: Yk. Kang et al., EXPRESSION OF MDR-1 IN REFRACTORY LYMPHOMA - QUANTITATION BY POLYMERASE CHAIN-REACTION AND VALIDATION OF THE ASSAY, Blood, 86(4), 1995, pp. 1515-1524
EXPRESSION OF MDR-1 IN REFRACTORY LYMPHOMA - QUANTITATION BY POLYMERASE CHAIN-REACTION AND VALIDATION OF THE ASSAY (VOL 86, PG 1515, 1995)
Authors: KANG YK ZHAN ZR REGIS J ALVAREZ M ROBEY R MEADOWS B DICKSTEIN B LEE JS OTSUKI T STETLERSTEVENSON M JAFFE ES SOLOMON D WILSON WH FOJO A BATES SE
Citation: Yk. Kang et al., EXPRESSION OF MDR-1 IN REFRACTORY LYMPHOMA - QUANTITATION BY POLYMERASE CHAIN-REACTION AND VALIDATION OF THE ASSAY (VOL 86, PG 1515, 1995), Blood, 86(12), 1995, pp. 4710-4710
PACLITAXEL IN DOXORUBICIN-REFRACTORY OR MITOXANTRONE-REFRACTORY BREAST-CANCER - A PHASE I II TRIAL OF 96-HOUR INFUSION/
Authors: WILSON WH BERG SL BRYANT G WITTES RE BATES S FOJO A STEINBERG SM GOLDSPIEL BR HERDT J OSHAUGHNESSY J BALIS FM CHABNER BA
Citation: Wh. Wilson et al., PACLITAXEL IN DOXORUBICIN-REFRACTORY OR MITOXANTRONE-REFRACTORY BREAST-CANCER - A PHASE I II TRIAL OF 96-HOUR INFUSION/, Journal of clinical oncology, 12(8), 1994, pp. 1621-1629
EPOCH CHEMOTHERAPY - TOXICITY AND EFFICACY IN RELAPSED AND REFRACTORYNON-HODGKINS-LYMPHOMA
Authors: WILSON WH BRYANT G BATES S FOJO A WITTES RE STEINBERG SM KOHLER DR JAFFE ES HERDT J CHESON BD CHABNER BA
Citation: Wh. Wilson et al., EPOCH CHEMOTHERAPY - TOXICITY AND EFFICACY IN RELAPSED AND REFRACTORYNON-HODGKINS-LYMPHOMA, Journal of clinical oncology, 11(8), 1993, pp. 1573-1582
Risultati: 1-8 |